INDIANAPOLIS (dpa-AFX) - Amylin Pharmaceuticals, Inc. (AMLN), Eli Lilly and Co. (LLY) and Alkermes, Inc. (ALKS) announced results from long-term extensions of the DURATION-1 and 3 studies evaluating BYDUREON, an investigational medication for type 2 diabetes.
The company stated that results from the DURATION-1 study showed that after three years, patients receiving BYDUREON experienced a significant reduction in A1C, a measure of average blood sugar over three months, and weight compared to baseline.
Separately, results from the DURATION-3 study showed that at 84 weeks, patients treated with BYDUREON experienced significantly greater A1C reduction from baseline, sustained weight loss and a lower risk of hypoglycemia than patients treated with Lantus, Amylin Pharma noted.
Commenting about BYDUREON, the company said that it is the proposed brand name for exenatide extended-release for injectable suspension and an investigational medication for type 2 diabetes designed to deliver continuous therapeutic levels of exenatide in a single weekly dose.
Copyright RTT News/dpa-AFX